Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyradiotherapyThoracic TumorsTumor, regardless of entityDiseaseBreast CancerLung Carcinoma, Non-Small CellLung Carcinoma, Small CellMerkel Cell CarcinomaTumor, Various OrgansSubgroupPD-L1+ICD10C34.-C44.9C50.-MeSHBreast NeoplasmsCarcinoma, Merkel CellCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaSequenceCASPIAN: DURV1500/CISP80/ETOP100, SCLC (PID1734) -|- DURV1500 maint. (PID1594)CASPIAN: DURV1500/CRBP5/ETOP100, SCLC (PID1593) -|- DURV1500 maint. (PID1594)CISP80/ETOP100/Radiation, SCLC, A (PID266) -|- IRIN60/CISP60, B (PID267)DOXO40/LURB2, SCLC (PID2628) -|- LURB3.2, maint. (PID2629)IMpower133: ATEZ1200/CRBP5/ETOP100, SCLC (PID1341) -|- ATEZ1200, maint. (PID1342)KEYNOTE-604: PEMB200/CISP75/ETOP100, SCLC (PID610) -|- PEMB200, maint. (PID631)KEYNOTE-604: PEMB200/CRBP5/ETOP100, SCLC (PID630) -|- PEMB200, maint. (PID631)ChemotherapyChemo-substanceAtezolizumabCarboplatinCisplatinCyclophosphamideDoxorubicinDurvalumabEpirubicinEtoposideHydrocortisoneIfosfamideIrinotecanLurbinectedinPaclitaxelPembrolizumabThiotepaTopotecanVincristineChemo-substanceAtezolizumabCarboplatinCisplatinCyclophosphamideDoxorubicinDurvalumabEpirubicinEtoposideHydrocortisoneIfosfamideIrinotecanLurbinectedinPaclitaxelPembrolizumabThiotepaTopotecanVincristineChemo-substanceAtezolizumabCarboplatinCisplatinCyclophosphamideDoxorubicinDurvalumabEpirubicinEtoposideHydrocortisoneIfosfamideIrinotecanLurbinectedinPaclitaxelPembrolizumabThiotepaTopotecanVincristineChemo-substanceAtezolizumabCarboplatinCisplatinCyclophosphamideDoxorubicinDurvalumabEpirubicinEtoposideHydrocortisoneIfosfamideIrinotecanLurbinectedinPaclitaxelPembrolizumabThiotepaTopotecanVincristineNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideNo. Substances1234567810Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseConsolidationInductionMaintenanceTherapy intentioncurativecurative or palliativepalliativeRisksAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaAstheniaCardiotoxicityConstipationCystitisDiarrheaDyspneaElectrolyte DisturbanceEmbolismEmetogenicityEmetogenicity (MASCC/ESMO)EsophagitisFatigueFebrile NeutropeniaHepatotoxicityHypertensionHypokalemiaHyponatremiaHypothyroidismLeukopeniaMyalgiasNephrotoxicityNeuropathyNeutropeniaOral MucositisPneumoniaPneumonitisPruritusRashSepsisThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorAisner JAix SBleehen, NEckardt JRFaivre-Finn CGatzemeier UGoto KHanna, NHanna NHong WKHorn LIhde, DJohnson DHLoehrer PJMaisch BMartinoni A Mavroudis DNeubauer MNiederle NNoda, KNoda KOkamoto HOtt PPawel JPaz-Ares LPujol JL et al.Quoix, EReck MRudin CSaito HSchiller JSchmittel, ASchmittel ASeifart UShah CSkarlos DVSmith, IESpigel DSpigel DRSundstrøm STakada MThatcher NTrigo JTurrisi ATYamamoto NDiseaseExtensive-Stage SCLC, Erstlinie, ECOG 0-1Extensive-Stage Small-Cell Lung CancerExtensive disease small cell lung cancerFortgeschrittenes kleinzelliges Lungenkarzinom (M1), Karnofsky-Index von 70% oder mehrfortgeschrittenes oder metastasiertes kleinzelliges Lungenkarzinom, Erstlinie, ECOG 0-2Kleinzelliges Lungenkarzinomkleinzelliges Lungenkarzinom, limited disease, ECOG 0-2Kleinzelliges Lungenkarzinom, limited und extensive disease, Erstlinie, ECOG 0-2kleinzelliges Lungenkarzinom, Stadium IV, Erstlinie, ECOG 0-1kleinzelliges Lungenkarzinom Stadium I-IIIB, Erstlinie, ECOG 0-2kleinzelliges Lungenkarzinom Stadium IV, Erstlinie, ECOG 0-2Maligner Perikarderguss, hämodynamisch relevantNSCLC, limited und extensive disease, Zweitlinie, Progress nach Erstlinie mind. 60 Tage nach ErstlinienkomplettierungSCLC, cT3/4 ohne Möglichkeit zur Radiatio oder extensive disease, ECOG 0-1SCLC, Erstlinientherapie bei Extensive-DiseaseSCLC, Erstlinientherapie bei Extensive-Disease SCLC, Erstlinientherapie bei extensive diseaseSCLC, Erstlinientherapie bei extensive disease SCLC, extensive disease, >70 Jahre und ECOG 0-2 oder < 70 Jahre und ECOG 3SCLC, extensive disease, Erstlinie, Patienten > 70 Jahre und ECOG 0-2 oder < 70 Jahre und ECOG 2SCLC, inoperabel, limited u extensive disease, männlichSCLC, LD und ED, komplette oder Teilremission nach Erstlinie, Therapiepause > 90 Tage, ECOG 0-2SCLC, limited diseaseSCLC, limited disease, ECOG 0-2SCLC, limited disease, ECOG: 0-2, CONVERT TrialSCLC, limited disease, kein Progress nach Radiochemotherapie, ECOG 0-1SCLC, limited disease, Stadium II-IVSCLC, limited disease exclusive Stadium ISCLC, limited disease ohne Möglichkeit zur Radiatio, extensive disease, Patienten älter als 70 Jahre, ECOG 0-2SCLC, limited und extended diseaseSCLC, limited und extended disease, ECOG 0-2, chemo-naivSCLC, limited und extensive diseaseSCLC, Progress > 90 Tage nach Ansprechen und Komplettierung der Erstlinie, ECOG 0-2SCLC, therapierefraktär oder rezidivierend, ECOG 0-2SCLC, therapierefraktär oder rezidivierend, mind. eine VortherapieSCLC, Zweitlinie, ECOG 0-2SCLC, Zweitlinie nach platinbasierter Therapie, ECOG 0-2SCLC, Zweitlinie nach platinbasierter Therapie ECOG 0-2SCLC, Zweitlinie nach Platinkombination oder TKI, PD-L1 Expression > 1%, ECOG 0-1SCLC extensive disease, chemo-naiv, ECOG 0-2SCLC limited u extensive diseaseSCLC limited u extensive disease, unbehandeltSCLC limited und extensive diseaseZweitlinientherapie des sensitiven kleinzelligen Lungenkarzinom, <75 Jahre, ECOG 0-2OriginAbteilung für thorakale Onkologie, Krankenhaus Grosshansdorf, Universität Hamburg, DeutschlandArbeitsgemeinschaft Internistische OnkologieAthens Medical Center, GreeceBarnard Cancer Center, Washington University School of MedicineBenjamin Franklin Campus Berlin, St. Marien Hospital Amberg, Universitätsmedizin Mainz, Westpfalzklinikum KaiserslauternBristol Lung Cancer Study GroupBritish Medical Research Council LU21 StudieCardiology Unit, Milan, ItalyCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, KEYNOTE-028Department of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain, ATLANTISDepartment of Medical Oncology, University of Crete, GriechenlandDepartment of Medicine, SUNY Upstate Medical University, Syracuse, USADepartment of Oncology, University Hospital of TrondheimDepartment of Thoracic Oncology, National Cancer Center Hospital East, Chiba, JapanDivision of Medical Oncology, Vanderbilt University Medical CenterDivision of Molecular and Clinical Cancer Sciences, University of Manchester, UKDivision of Molecular and Clinical Cancer Sciences, University of Manchester, UK, CONVERT studyEastern Cooperative Onkology GroupFrench Federation of Cancer InstitutesGreek Lung Cancer Cooperative GroupHamm-Kliniken, Marburg, DeutschlandHanna N, Indiana University, Hoosier Oncology GroupHoosier Oncology GroupHospital Universitario Virgen de la Victoria, Malaga, SpainJapan Clinical Oncology GroupJapan Clinical Oncology Group, Studie 9104Japan Clinical Oncology Group 9702Kansas City Cancer Center, US Oncology Research Inc.Lung Unit, Royal Marsden Hospital, Sutton, EnglandMedical Research Council Lung Cancer Working PartyMedical University of South Carolina, Charleston, USAMemorial Sloan Kettering Cancer Center, New York, NY, Keynote-604Pulmonology Unit, University Hospital Strasbourg, FrankreichSarah Cannon Research Institute, Nashville, ADRIATIC trialSarah Cannon Research Institute, Nashville, TN, SALUTE trialThe Center for Cancer Care and Research, St. Louis, USAThoracic Oncology Division, Shizuoka Cancer Center Hospital, Shizuoka, JapanUniversidad Complutense and Ciberonc, Madrid, Spain, CASPIAN trialUniversity of Maryland Cancer CenterVanderbilt University Medical Center, Nashville, IMpower133Westdeutsches Tumorzentrum EssenWest Japan Thoracic Oncology Group 9902Zentralkrankenhaus Gauting, Abteilung Onkologie, DeutschlandProtocols in Revision 65 protocols foundProtocols under revision.ACO II - Doxorubicin 60 / Cyclophosphamide 750 / Vincristine 1.5, Small Cell Lung Carcinoma (PID218)Atezolimab 1200 / Carboplatin 5 / Etoposide 100, Small Cell Lung Cancer (PID1341)Atezolizumab 1200, Lung Carcinoma, Small Cell, Maintenance (PID1342)Carboplatin 300 / Etoposide 100, Lung Carcinoma, Small Cell (PID210)Carboplatin 300 / Etoposide 140 / Vincristine 2, Small Cell Lung Carcinoma, Small Cell (PID207)Carboplatin 5 / Etoposide 100, Small Cell Lung Carcinoma, Small Cell (PID209)Carboplatin 5 / Etoposide 110 / Vincristine 2, Lung Carcinoma, Small Cell (limited disease) (PID1477)Carboplatin 5 / Etoposide 140, Lung Carcinoma, Small Cell (PID204)Carboplatin 5 / Etoposide 80, Lung Carcinoma, Small Cell (PID208)Carboplatin 5 / Etoposide 90 / Vincristine 2, Lung Carcinoma, Small Cell (extensive disease) (PID1476)Carboplatin 6 / Etoposide 100 / Radiation, Small Cell Lung Cancer (PID2267)Cisplatin 100 / Etoposide 100, Lung Carcinoma, Small Cell (PID201)Cisplatin 20 / Etoposide 75 / Ifosfamide 1,2, Small Cell Lung Carcinoma (PID233)Cisplatin 25 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID1256)Cisplatin 25 / Etoposide 60 / Irinotecan 90, Small Cell Lung Carcinoma (PID741)Cisplatin 25 / Etoposide 80, Lung Carcinoma, Small Cell (PID216)Cisplatin 30, Tumor, Various Organs (PID2371)Cisplatin 60 / Etoposide 120 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID264)Cisplatin 60 / Etoposide 120, Lung Carcinoma, Small Cell (PID217)Cisplatin 75 / Etoposide (100/200), Small Cell Lung Cancer (PID2558)Cisplatin 75 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID1254)Cisplatin 75 / Etoposide 100, Small Cell Lung Carcinoma (PID2266)Cisplatin 80 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID265)Cisplatin 80 / Etoposide 100 / Radiation, Small Cell Lung Cancer, Part A (PID266)Cisplatin 80 / Etoposide 100, Lung Carcinoma, Small Cell (PID214)Cisplatin 80 / Etoposide 120, Lung Carcinoma, Small Cell (PID211)Cisplatin 80 / Etoposide 80, Lung Carcinoma, Small Cell (PID215)Cyclophosphamide 1000 / Doxorubicin 45 / Etoposide 50, Small Cell Lung Carcinoma (PID260)Cyclophosphamide 1000 / Doxorubicin 50 / Vincristine2, Small Cell Lung Carcinoma, Small Cell (PID224)Cyclophosphamide 1000 / Etoposide (50/100) / Vincristine 2, Lung Carcinoma, Small Cell (PID225)Cyclophosphamide 2000 / Vincristine 2, Small Cell Lung Carcinoma, Small Cell (PID226)Doxorubicin 40 / Lurbinectedin 2, Small Cell Lung Cancer (PID2628)Durvalumab 1500 / Carboplatin 5 / Etoposide 100 - Durvalumab 1500 Maintenance, Small Cell Lung Carcinoma (PID1594)Durvalumab 1500 / Carboplatin 5 / Etoposide 100, Small Cell Lung Carcinoma (PID1593)Durvalumab 1500 / Cisplatin 80 / Etoposide 100, Small Cell Lung Carcinoma (PID1734)Durvalumab 1500, Small Cell Lung Cancer (PID2651)Epirubicin 50 / Cyclophosphamide 1000 / Vincristine 2, Small Cell Lung Cancer (PID259)Etoposide 110 / Paclitaxel 175 / Carboplatin 5, Lung Carcinoma, Small Cell (limited disease) (PID263)Etoposide 120 / Ifosfamide 5, Small Cell Lung Carcinoma, Small Cell (PID227)Etoposide 50, Small Cell Lung Carcinoma (PID244)Etoposide 90 / Paclitaxel 175 / Carboplatin 5, Lung Carcinoma, Small Cell (extensive disease) (PID200)Ifosfamide 5 / Carboplatin 300 / Etoposide (120/240) / Vincristine 1, Small Cell Lung Carcinoma (PID258)Irinotecan 50 / Carboplatin 5, Lung Carcinoma, Small Cell (PID241)Irinotecan 60 / Cisplatin 60, Lung Carcinoma, Small Cell (PID230)Irinotecan 60 / Cisplatin 60, Small Cell Lung Cancer, Part B (PID267)Irinotecan 65 / Cisplatin 30, Lung Carcinoma, Small Cell (PID229)Lurbinectedin 3,2, small cell lung cancer (PID1839)Lurbinectedin 3.2, Small Cell Lung Cancer, Maintenance (PID2629)Paclitaxel 175 / Cisplatin 80 / Etoposide 80, Small Cell Lung Cancer (PID232)Paclitaxel 80 / Carboplatin 2, Small Cell Lung Carcinoma (PID242)Paclitaxel 80, Small Cell Lung Carcinoma (PID245)Pembrolizumab 200 / Carboplatin 5 / Etoposide 100, Lung Carcinoma, Small Cell (PID630)Pembrolizumab 200 / Cisplatin 75 / Etoposide 100, Small Cell Lung Carcinoma, Small Cell (PID610)Pembrolizumab 200, Lung Carcinoma, Small Cell, Maintenance (PID631)Pembrolizumab 200, Small Cell Lung Carcinoma, Second Line (PID1345)Thiotepa 15 / Hydrocortisone 30, Tumor, Various Organs (PID2372)Topotecan 0.75 / Carboplatin 5, Lung Carcinoma, Small Cell (PID238)Topotecan 1 / Cisplatin 75, Small Cell Lung Carcinoma (PID235)Topotecan 1.25 / Carboplatin 5, Lung Carcinoma, Small Cell (PID237)Topotecan 1.5 / Cisplatin 75, Lung Carcinoma, Small Cell (PID236)Topotecan 1.5, small cell lung cancer (PID203)Topotecan 1.7 / Cisplatin 60, Lung Carcinoma, Small Cell (PID228)Topotecan 2, Small Cell Lung Carcinoma (Schiller variant) (PID234)Topotecan 2,3, Small Cell Lung Cancer (PID231)Topotecan 4, Small Cell Lung Carcinoma (PID240)
